Nathan J. Dowden

Nathan Dowden is the Chief Operating Officer of Entrada Therapeutics.

Prior to Entrada, Mr. Dowden was the SVP of Corporate Development at Rubius Therapeutics. There he worked to develop and integrate the company’s technology, capital formation and communication strategy in support of the organization’s evolution from Series A to public listing, and from discovery to clinical stage status.

Prior to Rubius, Mr. Dowden served as Managing Director at the Huron Consulting Group, leading life science client service, M&A, technology and publication efforts. He joined Huron after serving as a Managing Director of The Frankel Group LLC for 16 years. There he worked with biopharmaceutical companies on new venture creation, portfolio management and product commercialization. He has also worked at Ernest & Young in the healthcare practice, Searle Pharmaceuticals and CIGNA Healthcare.

Mr. Dowden holds a BS from the University of Connecticut and an MBA from the University of Chicago Booth School of Business.